Variations in the human soluble epoxide hydrolase gene and recurrence of atrial fibrillation after catheter ablation

International Journal of Cardiology

Volumn 168, Issue 4, 2013, Pages 3647-3651

  Wutzler, Alexander ^a,b   Kestler, Christoph ^a   Perrot, Andreas ^b   Loehr, Lena ^a,b   Huemer, Martin ^a   Parwani, Abdul Shokor ^a   Attanasio, Philipp ^a   Özcelik, Cemil ^a,d   Schunck, Wolf Hagen ^c   Gollasch, Maik ^a,b   Haverkamp, Wilhelm ^a   Boldt, Leif Hendrik ^a,b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Experimental and Clinical Research Center   (Germany)

^c MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^d Institut für Radiologie   (Germany)

Author keywords

Ablation; Atrial fibrillation; Epoxyeicosatrienoic acid; Single nucleotide polymorphism; Soluble epoxide hydrolase

Indexed keywords

EPOXIDE HYDROLASE;

ADULT; ARTICLE; CATHETER ABLATION; CONTROLLED STUDY; EPOXIDE HYDROLASE GENE; FEMALE; GENE FUNCTION; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC VARIABILITY; HEART ATRIUM FIBRILLATION; HOLTER MONITORING; HUMAN; HUMAN GENETICS; MAJOR CLINICAL STUDY; MALE; MOLECULAR PATHOLOGY; PRIORITY JOURNAL; RECURRENCE RISK; RECURRENT DISEASE; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

ABLATION; ATRIAL FIBRILLATION; EPOXYEICOSATRIENOIC ACID; SINGLE NUCLEOTIDE POLYMORPHISM; SOLUBLE EPOXIDE HYDROLASE;

AGED; ATRIAL FIBRILLATION; CATHETER ABLATION; EPOXIDE HYDROLASES; FEMALE; FOLLOW-UP STUDIES; GENETIC VARIATION; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RECURRENCE; RISK FACTORS; TREATMENT OUTCOME;

EID: 84886238001     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2013.05.010     Document Type: Article

References (47)

1. R. Cappato, H. Calkins, and S.A. Chen Update worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation Circ Arrhythm Electrophysiol 3 2010 32 38
2. H. Calkins, K.H. Kuck, and R. Cappato HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design J Interv Card Electrophysiol 33 2012 171 257
3. R.B. Schnabel, K.F. Kerr, and S.A. Lubitz Candidate Gene Association Resource (CARe) Atrial Fibrillation/Electrocardiography Working Group. Large-scale candidate gene analysis in whites and African Americans identifies IL6R polymorphism in relation to atrial fibrillation: the National Heart, Lung, and Blood Institute's Candidate Gene Association Resource (CARe) project Circ Cardiovasc Genet 4 2011 557 564
4. M.H. Gollob, D.L. Jones, and A.D. Krahn Somatic mutations in the connexin 40 gene (GJA5) in atrial fibrillation N Engl J Med 354 2006 2677 2688
5. C. Fatini, E. Sticchi, and M. Genuardi Analysis of minK and eNOS genes as candidate loci for predisposition to nonvalvular atrial fibrillation Eur Heart J 27 2006 1712 1718
6. R.C. Wirka, S. Gore, and D.R. Van Wagoner A common connexin-40 gene promoter variant affects connexin-40 expression in human atria and is associated with atrial fibrillation Circ Arrhythm Electrophysiol 4 2011 87 93
7. C.T. Tsai, D.L. Wang, and W.P. Chen Angiotensin II increases expression of alpha1C subunit of L-type calcium channel through a reactive oxygen species and cAMP response element-binding protein-dependent pathway in HL-1 myocytes Circ Res 100 2007 1476 1485
8. J.M. Juang, Y.R. Chern, and C.T. Tsai The association of human connexin 40 genetic polymorphisms with atrial fibrillation Int J Cardiol 116 2007 107 112
9. L.P. Lai, M.J. Su, and H.M. Yeh Association of the human MinK gene 38G allele with atrial fibrillation: evidence of possible genetic control on the pathogenesis of atrial fibrillation Am Heart J 144 2002 485 490
10. L.Y. Chen, J.D. Ballew, K.J. Herron, R.J. Rodeheffer, and T.M. Olson A common polymorphism in SCN5A is associated with lone atrial fibrillation Clin Pharmacol Ther 81 2007 35 41
11. D. Darbar, A.A. Motsinger, M.D. Ritchie, J.V. Gainer, and D.M. Roden Polymorphism modulates symptomatic response to antiarrhythmic drug therapy in patients with lone atrial fibrillation Heart Rhythm 4 2007 743 749
12. M.T. Nyberg, B. Stoevring, E.R. Behr, L.S. Ravn, W.J. McKenna, and M. Christiansen The variation of the sarcolipin gene (SLN) in atrial fibrillation, long QT syndrome and sudden arrhythmic death syndrome Clin Chim Acta 375 2007 87 91
13. C.T. Tsai, L.P. Lai, and J.J. Hwang Renin-angiotensin system component expression in the HL-1 atrial cell line and in a pig model of atrial fibrillation J Hypertens 26 2008 570 582
14. B. Parvez, J. Vaglio, and S. Rowan Symptomatic response to antiarrhythmic drug therapy is modulated by a common single nucleotide polymorphism in atrial fibrillation J Am Coll Cardiol 60 2012 539 545
15. F. Lombardi, S. Belletti, P.M. Battezzati, R. Pacciolla, and M.L. Biondi MMP-1 and MMP-3 polymorphism and arrhythmia recurrence after electrical cardioversion in patients with persistent atrial fibrillation J Cardiovasc Med (Hagerstown) 12 2011 37 42
16. D. Husser, V. Adams, C. Piorkowski, G. Hindricks, and A. Bollmann Chromosome 4q25 variants and atrial fibrillation recurrence after catheter ablation J Am Coll Cardiol 55 2010 747 753
17. J.D. Imig, and B.D. Hammock Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases Nat Rev 8 2009 794 805
18. K. Node, Y. Huo, and X. Ruan Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids Science 285 1999 1276 1279
19. H.C. Lee, T. Lu, N.L. Weintraub, M. VanRollins, A.A. Spector, and E.F. Shibata Effects of epoxyeicosatrienoic acids on the cardiac sodium channels in isolated rat ventricular myocytes J Physiol 519 1999 153 168
20. J. Chen, J.H. Capdevila, D.C. Zeldin, and R.L. Rosenberg Inhibition of cardiac L-type calcium channels by epoxyeicosatrienoic acids Mol Pharmacol 55 1999 288 295
21. D.C. Zeldin Epoxygenase pathways of arachidonic acid metabolism J Biol Chem 276 2001 36059-2
22. B.D. Przybyla-Zawislak, P.K. Srivastava, and J. Vazquez-Matias Polymorphisms in human soluble epoxide hydrolase Mol Pharmacol 64 2003 482 490
23. M. Fornage, C.R. Lee, and P.A. Doris The soluble epoxide hydrolase gene harbors sequence variation associated with susceptibility to and protection from incident ischemic stroke Hum Mol Genet 14 2005 2829 2837
24. C.R. Lee, K.E. North, and M.S. Bray Genetic variation in soluble epoxide hydrolase (EPHX2) and risk of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) study Hum Mol Genet 15 2006 1640 1649
25. C. Fava, M. Montagnana, and E. Danese Homozygosity for the EPHX2 K55R polymorphism increases the long-term risk of ischemic stroke in men: a study in Swedes Pharmacogenet Genomics 20 2010 94 103
26. A. Gschwendtner, S. Ripke, and T. Freilinger Genetic variation in soluble epoxide hydrolase (EPHX2) is associated with an increased risk of ischemic stroke in white Europeans Stroke 39 2008 1593 1596
27. H. Qiu, N. Li, J.Y. Liu, T.R. Harris, B.D. Hammock, and N. Chiamvimonvat Soluble epoxide hydrolase inhibitors and heart failure Cardiovasc Ther 29 2011 99 111
28. J. Monti, J. Fischer, and S. Paskas Soluble epoxide hydrolase is a susceptibility factor for heart failure in a rat model of human disease Nat Genet 40 2008 529 537
29. A. Wutzler, S. Rolf, and M. Huemer Safety aspects of deep sedation during catheter ablation of atrial fibrillation Pacing Clin Electrophysiol 35 2012 38 43
30. I.P. Koerner, R. Jacks, and A.E. DeBarber Polymorphisms in the human soluble epoxide hydrolase gene ephx2 linked to neuronal survival after ischemic injury J Neurosci 27 2007 4642 4649
31. M.J. Merkel, L. Liu, and Z. Cao Inhibition of soluble epoxide hydrolase preserves cardiomyocytes: role of STAT3 signaling Am J Physiol Heart Circ Physiol 298 2 2010 H679 H687
32. M. Fornage, E. Boerwinkle, P.A. Doris, D. Jacobs, K. Liu, and N.D. Wong Polymorphism of the soluble epoxide hydrolase is associated with coronary artery calcification in African-American subjects: the Coronary Artery Risk Development In Young Adults (CARDIA) study Circulation 109 2004 335 339
33. M.P. Hutchens, T. Nakano, J. Dunlap, R.J. Traystman, P.D. Hurn, and N.J. Alkayed Soluble epoxide hydrolase gene deletion reduces survival after cardiac arrest and cardiopulmonary resuscitation Resuscitation 76 2008 89 94
34. T. Frömel, B. Jungblut, and J. Hu Soluble epoxide hydrolase regulates hematopoietic progenitor cell function via generation of fatty acid diols Proc Natl Acad Sci USA 109 2012 9995 10000
35. Y.F. Xiao, L. Huang, and J.P. Morgan Cytochrome P450, a novel system modulating Ca2 + channels and contraction in mammalian heart cells J Physiol 508 1998 777 792
36. Y.F. Xiao, Q. Ke, and J.M. Seubert Enhancement of cardiac L-type Ca2 + currents in transgenic mice with cardiac-specific overexpression of CYP2J2 Mol Pharmacol 66 2004 1607 1616
37. Y.F. Xiao Cyclic AMP-dependent modulation of cardiac L-type Ca2 + and transient outward K + channel activities by epoxyeicosatrienoic acids Prostaglandins Other Lipid Mediat 82 2007 11 18
38. A.A. Spector, and A.W. Norris Action of epoxyeicosatrienoic acids on cellular function Am J Physiol Cell Physiol 292 2007 C996 C1012
39. J. Lee, M. Dahl, P. Grande, A. Tybjaerg-Hansen, and B.G. Nordestgaard Genetically reduced soluble epoxide hydrolase activity and risk of stroke and other cardiovascular disease Stroke 41 2010 27 33
40. L. Zhang, H. Ding, and J. Yan Genetic variation in cytochrome P450 2J2 and soluble epoxide hydrolase and risk of ischemic stroke in a Chinese population Pharmacogenet Genomics 18 2008 45 51
41. N. Voigt, and D. Dobrev Ion channel remodelling in atrial fibrillation Eur Cardiol 7 2011 97 103
42. S.J. Thomson, A. Askari, and D. Bishop-Bailey Anti-inflammatory effects of epoxyeicosatrienoic acids Int J Vasc Med 2012 605101
43. G.S. Ginsburg, S.H. Shah, and J.J. McCarthy Taking cardiovascular genetic association studies to the next level J Am Coll Cardiol 50 2007 930 932
44. J.M. Seubert, D.C. Zeldin, K. Nithipatikom, and G.J. Gross Role of epoxyeicosatrienoic acids in protecting the myocardium following ischemia/reperfusion injury Prostaglandins Other Lipid Mediat 82 2007 50 59
45. A.L. Sander, H. Jakob, and K. Sommer Cytochrome P450-derived epoxyeicosatrienoic acids accelerate wound epithelialization and neovascularization in the hairless mouse ear wound model Langenbecks Arch Surg 396 8 2011 1245 1253
46. K.G. Proctor, S. Shatkin Jr., P.M. Kaminski, J.R. Falck, and J.H. Capdevila Modulation of arteriolar blood flow by inhibitors of arachidonic acid oxidation after thermal injury: possible role for a novel class of vasodilator metabolites Circulation 77 5 1988 1185 1196
47. F. Ouyang, M. Antz, and S. Ernst Recovered pulmonary vein conduction as a dominant factor for recurrent atrial tachyarrhythmias after complete circular isolation of the PVs: lessons from double Lasso technique Circulation 111 2005 127 135